קלוד
unipharm ltd, israel - clopidogrel as hydrogen sulfate - טבליה - clopidogrel as hydrogen sulfate 75 mg - clopidogrel
קלופידוגרל טבע
teva pharmaceutical industries ltd, israel - clopidogrel as bisulfate - טבליה - clopidogrel as bisulfate 75 mg - clopidogrel
הלדול דקאנואס
j-c health care ltd - haloperidol as decanoate - תמיסה להזרקה - haloperidol as decanoate 100 mg/ml - haloperidol
קלופידקסל 75
dexcel pharma technologies ltd - clopidogrel as besylate 75 mg - film coated tablets - clopidogrel - clopidogrel is indicated for the prevention of atherothrombotic events as follows:• recent mi, recent stroke or established peripheral arterial disease: patients suffering from myocardial infarction (from a few days until less than 35 days), ischaemic stroke (from 7 days until less than 6 months) or established peripheral arterial disease. for patients with a history of recent myocardial infarction (mi), recent stroke or established peripheral arterial disease, clopidogrel has been shown to reduce the rate of a combined endpoint of new ischemic stroke (fatal or not), new mi (fatal or not) and other vascular death.• acute coronary syndrome: for patients with acute coronary syndrome (non-st segment elevation acute coronary syndrome (unstable angina/non-q-wave mi) or st segment elevation acute myocardial infarction), in combination with asa in medically treated patients eligible for thrombolytic therapy, and those who are to be managed with percutaneous coronary intervention (with or without stent) or cabg clopi
קלופיד 75 מ"ג
taro international ltd - clopidogrel 75 mg - film coated tablets - clopidogrel - clopidogrel is indicated in adults for the prevention of atherothrombotic events as follows:patients suffering from myocardial infarction (from a few days until less than 35 days), ischaemic stroke (from 7 days until less than 6 months) or established peripheral arterial disease.patients suffering from acute coronary syndrome- non-st segment elevation acute coronary syndrome (unstable angina/non-q-wave myocardial infarction (mi)), including patients undergoing a stent replacement following percutaneous coronary intervention, in combination with acetylsalicylic acid (asa). - st segment elevation acute myocardial infarction, in combination with asa in medically treated patients eligible for thrombolytic therapy
קלופיד 75 מ"ג
taro international ltd - clopidogrel 75 mg - film coated tablets - clopidogrel - clopidogrel is indicated in adults for the prevention of atherothrombotic events as follows:patients suffering from myocardial infarction (from a few days until less than 35 days), ischaemic stroke (from 7 days until less than 6 months) or established peripheral arterial disease.patients suffering from acute coronary syndrome- non-st segment elevation acute coronary syndrome (unstable angina/non-q-wave myocardial infarction (mi)), including patients undergoing a stent replacement following percutaneous coronary intervention, in combination with acetylsalicylic acid (asa). - st segment elevation acute myocardial infarction, in combination with asa in medically treated patients eligible for thrombolytic therapy
הלדול אמפולות
j-c health care ltd - haloperidol - תמיסה להזרקה - haloperidol 5 mg/ml - haloperidol
פלויקס 300 מ"ג
sanofi - aventis israel ltd - clopidogrel as hydrogen sulfate 300 mg - film coated tablets - clopidogrel - prevention of atherotrobmotic eventsclopidogrel is indicated in :• adult patients suffering from myocardial infarction (from a few days until less than 35 days), ischaemic stroke (from 7 days until less than 6 months) or established peripheral arterial disease.• adult patients suffering from acute coronary syndrome- non-st segment elevation acute coronary syndrome (unstable angina/non-q-wave myocardial infarction (mi)), including patients undergoing a stent placement following percutaneous coronary intervention, in combination with acetylsalicylic acid (asa). - st segment elevation acute myocardial infarction, in combination with asa in medically treated patients eligible for thrombolytic therapyprevention of atherotrobmotic and thromboembolic events in atrial fibrillation: in adult patients with atrial fibrillation who have at least one risk factor for vascular events, are not suitable for the treatment with vitamin k antagonists (vka) anti-thrombin or anti factor xa, and who have a low bleeding risk, clopid
קלופידול פלוס וטרינרי
phibro animal health ltd., israel - clopidol; methyl benzoquate - אבקה מסיסה - clopidol 20 %; methyl benzoquate 1.66 % - for prevention of eimeria susceptible to clopidol and methylbenzoquate in broilers.
קלופידול 25 וטרינרי
phibro animal health ltd., israel - clopidol - אבקה - clopidol 255 g/kg